Review of Atopic Dermatitis and Topical Therapies

被引:72
作者
Mayba, Julia N. [1 ]
Gooderham, Melinda J. [2 ,3 ,4 ]
机构
[1] Univ Manitoba, Coll Med, Fac Hlth Sci, Winnipeg, MB, Canada
[2] Queens Univ, Kingston, ON, Canada
[3] SKiN Ctr Dermatol, 775 Monaghan Rd, Peterborough, ON K9J 5K2, Canada
[4] Probity Med Res, Waterloo, ON, Canada
关键词
atopic dermatitis; topical corticosteroids; topical calcineurin inhibitors; topical Janus kinase inhibitors; topical phosphodiesterase-4 inhibitors; WET-WRAP DRESSINGS; TACROLIMUS OINTMENT; CALCINEURIN INHIBITORS; FLUTICASONE PROPIONATE; STAPHYLOCOCCUS-AUREUS; SKIN MICROBIOME; FOOD ALLERGY; DOUBLE-BLIND; CHILDREN; BARRIER;
D O I
10.1177/1203475416685077
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Atopic dermatitis is one of the most common skin disorders in the developed world, affecting up to 20% of children and 1% to 3% of adults. This review concisely explains the pathophysiology and epidemiology of atopic dermatitis, as well as potential challenges facing its successful treatment. Furthermore, mainstay topical treatment modalities are evaluated, such as emollients, topical corticosteroids, and topical calcineurin inhibitors. The use of topical corticosteroids and topical calcineurin inhibitors in combination is discussed, as studies have indicated encouraging results. The proactive use of topical corticosteroids and topical calcineurin inhibitors is also investigated, in order to bring attention to a new possibility in long-term management of atopic dermatitis. Last, new and upcoming topical medications are described, including Janus kinase inhibitors, phosphodiesterase-4 inhibitors, and benvitimod. Although topical corticosteroids and topical calcineurin inhibitors can be very effective in the treatment of atopic dermatitis, it is important that practitioners are aware of mechanistically unique and new treatments for patients for whom more traditional topical therapies have failed. Overall, this review article hopes to serve as a comprehensive overview of currently available topical treatments for atopic dermatitis, while shedding light on new treatments coming in the future.
引用
收藏
页码:227 / 236
页数:10
相关论文
共 75 条
  • [1] Abramovits William, 2006, J Drugs Dermatol, V5, P236
  • [2] Comparison of Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse: A Randomized Double-blind Controlled Multicentre Clinical Trial
    Akerstrom, Ulf
    Reitamo, Sakari
    Langeland, Tor
    Berg, Mats
    Rustad, Lisbeth
    Korhonen, Laura
    Loden, Marie
    Wiren, Karin
    Grande, Mats
    Skare, Petra
    Svensson, Ake
    [J]. ACTA DERMATO-VENEREOLOGICA, 2015, 95 (05) : 587 - 592
  • [3] The role of food allergy in the atopic march
    Allen, K. J.
    Dharmage, S. C.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2010, 40 (10) : 1439 - 1441
  • [4] [Anonymous], CURR MED RES OPIN
  • [5] Epidermal interleukin-1α generation is amplified at low humidity:: implications for the pathogenesis of inflammatory dermatoses
    Ashida, Y
    Ogo, M
    Denda, M
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (02) : 238 - 243
  • [6] Interventions to Increase Treatment Adherence in Pediatric Atopic Dermatitis: A Systematic Review
    Bass, Alexandria M.
    Anderson, Kathryn L.
    Feldman, Steven R.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2015, 4 (02): : 231 - 242
  • [7] Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study
    Berth-Jones, J
    Damstra, RJ
    Golsch, S
    Livden, JK
    Van Hooteghem, O
    Allegra, F
    Parker, CA
    [J]. BRITISH MEDICAL JOURNAL, 2003, 326 (7403): : 1367 - 1370
  • [8] Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
    Bissonnette, R.
    Papp, K. A.
    Poulin, Y.
    Gooderham, M.
    Raman, M.
    Mallbris, L.
    Wang, C.
    Purohit, V.
    Mamolo, C.
    Papacharalambous, J.
    Ports, W. C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (05) : 902 - 911
  • [9] Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial
    Bissonnette, R.
    Poulin, Y.
    Zhou, Y.
    Tan, J.
    Hong, H. C.
    Webster, J.
    Ip, W.
    Tang, L.
    Lyle, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04) : 853 - 860
  • [10] Macrolactam immunomodulators for topical treatment of inflammatory skin diseases
    Bornhövd, E
    Burgdorf, WHC
    Wollenberg, A
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (05) : 736 - 743